Back to Research Hub
Tango Therapeutics, Inc.
TNGX
$31.56+0.63 (+2.04%)
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase…
StreetsValue research for Tango Therapeutics, Inc. (TNGX)
Members get the full report for Tango Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.